Precision Gene Editing Strategies with CRISPR-Cas9 for Advancing Cancer Immunotherapy and Alzheimer's Disease
DOI:
https://doi.org/10.60087/jklst.v3.n4.p11Keywords:
Cancer Immunotherapy, Alzheimer’s Disease, Biomedical, Genetics, CRISPR-Cas9Abstract
Precision medicine approaches such as gene editing via clustered regularly interspaced short palindromic repeat (CRISPR) and their associated protein (Cas-9) are revolutionizing treatment strategies for complex diseases such as Alzheimer and cancer. In this review, we explore the application of CRISPR-Cas9 in advancing therapies for these conditions, as well as its potential in targeting senescent cells. Since the risk of Alzheimer’s disease is strongly associated with genetic mutations and variations, the use of gene editing technologies to rectify these genetic errors by modifying disease-associated proteins becomes relevant. For cancer, to enhance immunotherapy approaches, modification of immune cells have been utilized to improve their anti-tumor efficacy. Additionally, the review also investigates the role of CRISPR-Cas9 in targeting senescent cells, which are implicated in both aging-related disorders and cancer progression. While challenges remain in introducing delivery methods and specificity, CRISPR-Cas9 represents a significant advancement in developing targeted, personalized treatments for these challenging health issues.
Downloads
References
National Institute on Aging, “Alzheimer’s Disease fact sheet,” National Institute on Aging, 2023. https://www.nia.nih.gov/health/alzheimers-and-dementia/alzheimers-disease-fact-sheet
D. Gupta et al., “CRISPR-Cas9 system: A new-fangled dawn in gene editing,” Life Sciences, vol. 232, p. 116636, Sep. 2019, doi: https://doi.org/10.1016/j.lfs.2019.116636.
C. Thomas, “What are the pros and cons of CRISPR-Cas9? | IDT,” Integrated DNA Technologies, Oct. 17, 2023. https://sg.idtdna.com/pages/education/decoded/article/crispr-cas9-what-are-the-pros-and-cons
A. A. Rabaan et al., “Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction,” Current Oncology, vol. 30, no. 2, pp. 1954–1976, Feb. 2023, doi: https://doi.org/10.3390/curroncol30020152.
S. Vimal, I. H. Madar, L. Thirumani, L. Thangavelu, and A. M. Sivalingam, “CRISPR/Cas9: Role of genome editing in cancer immunotherapy,” Oral Oncology Reports, vol. 10, p. 100251, Jun. 2024, doi: https://doi.org/10.1016/j.oor.2024.100251.
B. G. Childs et al., “Senescent cells: an emerging target for diseases of ageing,” Nature Reviews Drug Discovery, vol. 16, no. 10, pp. 718–735, Jul. 2017, doi: https://doi.org/10.1038/nrd.2017.116.
N. C. Barman et al., “CRISPR-Cas9: A Promising Ge-nome Editing Therapeutic Tool for Alzheimer’s Disease—A Narrative Review,” Neurology and Therapy, vol. 9, no. 2, pp. 419–434, Oct. 2020, doi: https://doi.org/10.1007/s40120-020-00218-z.
L. Lu, X. Yu, Y. Cai, M. Sun, and H. Yang, “Application of CRISPR/Cas9 in Alzheimer’s Disease,” Frontiers in Neuroscience, vol. 15, Dec. 2021, doi: https://doi.org/10.3389/fnins.2021.803894.
M. Asmamaw and B. Zawdie, “Mechanism and Appli-cations of CRISPR/Cas-9-Mediated Genome Editing,” Bi-ologics : Targets & Therapy, vol. 15, no. 1, pp. 353–361, Aug. 2021, doi: https://doi.org/10.2147/BTT.S326422.
M. Asmamaw and B. Zawdie, “Mechanism and Ap-plications of CRISPR/Cas-9-Mediated Genome Editing,” Biologics : Targets & Therapy, vol. 15, no. 1, pp. 353–361, Aug. 2021, doi: https://doi.org/10.2147/BTT.S326422.
S.-W. Wang et al., “Current applications and future perspective of CRISPR/Cas9 gene editing in cancer,” Mo-lecular Cancer, vol. 21, no. 1, Feb. 2022, doi: https://doi.org/10.1186/s12943-022-01518-8.
L. M. De Plano, G. Calabrese, S. Conoci, S. P. P. Gug-lielmino, S. Oddo, and A. Caccamo, “Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disor-ders,” International Journal of Molecular Sciences, vol. 23, no. 15, p. 8714, Jan. 2022, doi: https://doi.org/10.3390/ijms23158714.
L. Guan et al., “CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders,” Molecular Neurobiology, Nov. 2021, doi: https://doi.org/10.1007/s12035-021-02638-w.
“CPR23 - Cancer in 2023,” Cancer Progress Report. https://cancerprogressreport.aacr.org/progress/cpr23-contents/cpr23-cancer-in-2023/
H. J. Pandya et al., “A microfluidic platform for drug screening in a 3D cancer microenvironment,” Biosensors and Bioelectronics, vol. 94, pp. 632–642, Aug. 2017, doi: https://doi.org/10.1016/j.bios.2017.03.054.
H. J. Pandya et al., “Label-free electrical sensing of bacteria in eye wash samples: A step towards point-of-care detection of pathogens in patients with infectious keratitis,” Biosensors and Bioelectronics, vol. 91, pp. 32–39, May 2017, doi: https://doi.org/10.1016/j.bios.2016.12.035.
M. Safavieh et al., “Paper microchip with a gra-phene-modified silver nano-composite electrode for elec-trical sensing of microbial pathogens,” Nanoscale, vol. 9, no. 5, pp. 1852–1861, 2017, doi: https://doi.org/10.1039/c6nr06417e.
J. R. Quesada et al., “Treatment of hairy cell leukemia with recombinant alpha-interferon,” Blood, vol. 68, no. 2, pp. 493–497, Aug. 1986, Available: https://pubmed.ncbi.nlm.nih.gov/3730612/
S. A. Rosenberg, “IL-2: The First Effective Immuno-therapy for Human Cancer,” The Journal of Immunology, vol. 192, no. 12, pp. 5451–5458, Jun. 2014, doi: https://doi.org/10.4049/jimmunol.1490019.
Jong Ho Cha, L. F. Chan, M. Song, and Mien Chie Hung, “New Approaches on Cancer Immunotherapy,” Cold Spring Harbor Perspectives in Medicine, vol. 10, no. 8, pp. a036863–a036863, Aug. 2020, doi: https://doi.org/10.1101/cshperspect.a036863.
“PROLEUKIN ® (aldesleukin) for injection, for in-travenous infusion Rx Only.” Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf
G. Kwok, T. C. C. Yau, J. W. Chiu, E. Tse, and Y.-L. Kwong, “Pembrolizumab (Keytruda),” Human Vaccines & Immunotherapeutics, vol. 12, no. 11, pp. 2777–2789, Jul. 2016, doi: https://doi.org/10.1080/21645515.2016.1199310.
C. Phillips, “Lifileucel First Cellular Therapy Ap-proved for Cancer - NCI,” www.cancer.gov, Mar. 05, 2024. https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma
C. for B. E. and Research, “AMTAGVI,” FDA, 2024, Available: https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/amtagvi
Kulkarni S, Dhingra K, Verma S., "Applications of CMUT Technology in Medical Diagnostics: From Photoa-coustic to Ultrasonic Imaging", International Journal of Science and Research (IJSR), Volume 13 Issue 6, June 2024, pp. 1264-1269, https://www.ijsr.net/archive/v13i6/SR24619062609.pdf
GhavamiNejad P, GhavamiNejad A, Zheng H, Dhingra K, Samarikhalaj M, Poudineh M., “A Conductive Hydrogel Microneedle‐Based Assay Integrating PEDOT:PSS and Ag‐Pt Nanoparticles for Real‐Time, Enzyme‐Less, and Elec-trochemical Sensing of Glucose,” Advanced Healthcare Materials, vol. 12, no. 1, Oct. 2022, doi: https://doi.org/10.1002/adhm.202202362.
S. Odinotski et al., “A Conductive Hydrogel‐Based Microneedle Platform for Real‐Time pH Measurement in Live Animals,” Small, vol. 18, no. 45, Sep. 2022, doi: https://doi.org/10.1002/smll.202200201.
S. Maleki Vareki, C. Garrigós, and I. Duran, “Bi-omarkers of response to PD-1/PD-L1 inhibition,” Critical Reviews in Oncology/Hematology, vol. 116, pp. 116–124, Aug. 2017, doi: https://doi.org/10.1016/j.critrevonc.2017.06.001.
R. S. Riley and E. S. Day, “Gold nanoparti-cle-mediated photothermal therapy: applications and op-portunities for multimodal cancer treatment,” Wiley inter-disciplinary reviews. Nanomedicine and nanobiotechnology, vol. 9, no. 4, p. 10.1002/wnan.1449, 2017, doi: https://doi.org/10.1002/wnan.1449.
Z. Liu et al., “Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy,” Molecular Cancer, vol. 22, no. 1, Feb. 2023, doi: https://doi.org/10.1186/s12943-023-01738-6.
J. Zhang et al., “Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL,” Nature, vol. 609, no. 7926, pp. 369–374, Aug. 2022, doi: https://doi.org/10.1038/s41586-022-05140-y.
A. A. Rabaan et al., “Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction,” Current Oncology, vol. 30, no. 2, pp. 1954–1976, Feb. 2023, doi: https://doi.org/10.3390/curroncol30020152.
M. Collado, M. A. Blasco, and M. Serrano, “Cellular Senescence in Cancer and Aging,” Cell, vol. 130, no. 2, pp. 223–233, Jul. 2007, doi: https://doi.org/10.1016/j.cell.2007.07.003.
National Cancer Institute, “https://www.cancer.gov/publications/dictionaries/cancer-terms/def/senescence,” www.cancer.gov, Feb. 02, 2011. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/senescence
J. M. van Deursen, “The role of senescent cells in ageing,” Nature, vol. 509, no. 7501, pp. 439–446, May 2014, doi: https://doi.org/10.1038/nature13193.
Y. Li et al., “Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocel-lular carcinoma,” Theranostics, vol. 14, no. 9, pp. 3526–3547, 2024, doi: https://doi.org/10.7150/thno.95971.
C. von Kobbe, “Targeting senescent cells: approaches, opportunities, challenges,” Aging, vol. 11, no. 24, Nov. 2019, doi: https://doi.org/10.18632/aging.102557.
P. Carpintero-Fernández et al., “Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence,” Cell death and disease, vol. 13, no. 2, Feb. 2022, doi: https://doi.org/10.1038/s41419-022-04569-3.
W. J and B. A, “Current Understanding of Alzheimer’s Disease Diagnosis and Treatment,” F1000Research, Jul. 31, 2018. https://pubmed.ncbi.nlm.nih.gov/30135715/
S. P. Raikwar et al., “Neuro-Immuno-Gene- and Ge-nome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet?,” Journal of Alzheimer’s Disease, vol. 65, no. 2, pp. 321–344, doi: https://doi.org/10.3233/JAD-180422.
B. György et al., “CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s Disease,” Molecular Therapy - Nucleic Acids, vol. 11, pp. 429–440, Jun. 2018, doi: https://doi.org/10.1016/j.omtn.2018.03.007.
H. Park et al., “In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates defi-cits in mouse models of Alzheimer’s disease,” Nature Neuroscience, vol. 22, no. 4, pp. 524–528, Mar. 2019, doi: https://doi.org/10.1038/s41593-019-0352-0.
K. S. Allemailem et al., “Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer man-agement,” Cancer Communications, vol. 42, no. 12, pp. 1257–1287, Oct. 2022, doi: https://doi.org/10.1002/cac2.12366.
A. Dimitri, F. Herbst, and J. A. Fraietta, “Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing,” Molecular Cancer, vol. 21, no. 1, Mar. 2022, doi: https://doi.org/10.1186/s12943-022-01559-z.
N. Thapar, M. A. F. Eid, N. Raj, T. Kantas, H. S. Billing, and D. Sadhu, “Application of CRISPR/Cas9 in the man-agement of Alzheimer’s disease and Parkinson’s disease: a review,” Annals of Medicine and Surgery, vol. 86, no. 1, p. 329, Jan. 2024, doi: https://doi.org/10.1097/MS9.0000000000001500.
E. Passeri et al., “Alzheimer’s Disease: Treatment Strategies and Their Limitations,” International Journal of Molecular Sciences, vol. 23, no. 22, p. 13954, Nov. 2022, doi: https://doi.org/10.3390/ijms232213954.
K. Blennow and H. Zetterberg, “Biomarkers for alz-heimer’s disease: Current status and prospects for the future,” Journal of Internal Medicine, vol. 284, no. 6, pp. 643–663, Aug. 2018, doi: https://doi.org/10.1111/joim.12816.
K. Gąsiorowski et al., “Current and Near-Future Treatment of Alzheimer’s Disease,” Current Neurophar-macology, vol. 19, Dec. 2021, doi: https://doi.org/10.2174/1570159x19666211202124239.
A. Rahimi et al., “Application of CRISPR/Cas9 System in the Treatment of Alzheimer’s Disease and Neurodegen-erative Diseases,” Molecular neurobiology, Apr. 2024, doi: https://doi.org/10.1007/s12035-024-04143-2.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Journal of Knowledge Learning and Science Technology ISSN: 2959-6386 (online)
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2024 All rights reserved by the respective authors and JKLST.
Copyright: © The Author(s), 2024. Published by 